Press "Enter" to skip to content

FDA panel votes unanimously in favor of Horizon’s thyroid eye disease drug

If approved, teprotumumab, a type of immunotherapy, is expected to become a standard of care for the vision-threatening autoimmune disorder, which currently has no approved therapies.

Original source: https://health.economictimes.indiatimes.com/news/pharma/fda-panel-votes-unanimously-in-favor-of-horizons-thyroid-eye-disease-drug/72576557?utm_source=RSS&utm_medium=ETRSS

Also Read:   Bharat Biotech-ICMR developed Covaxin is safe, show preliminary phase I results